Dual-action therapies are emerging as a groundbreaking approach in the fight against concurrently HIV and cancer. These treatments target multiple pathways within infected cells, offering {a{ promise of improved efficacy and reduced side effects compared to traditional single-target approaches. By combining different therapeutic modalities, dual-ac